title: [Human rotavirus vaccine].
abstract: Since the presentation of the clinical trial reports showing the excellent efficacy and safety of the two human rotavirus vaccines (Rotarix and RotaTeq), the human rotavirus vaccines have received worldwide attention. The two vaccines have been approved in more than 100 countries, and were included in routine immunization schedule in about 30 countries. The effectiveness of the two vaccines exceeded our expectations, and severe rotavirus gastroenteritis cases have been greatly reduced. Also in Japan, administration of Rotarix started just last November, and RotaTeq will be also started soon. On this occasion, composition, characteristics, and effectiveness of these vaccines are described, and some points relating to the vaccination such as intussusception, cross protection, shedding and so on are also discussed.
authors.affiliation: Department of Virology and Parasitology, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan. kokitani@fujita-hu.ac.jp
authors.forename: Koki
authors.initials: K
authors.lastname: Taniguchi
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003108:Colonic Diseases / Q000209:etiology; D005759:Gastroenteritis / Q000517:prevention & control* / Q000821:virology*; D006801:Humans; D007443:Intussusception / Q000209:etiology; D051379:Mice; D012400:Rotavirus Infections; D022243:Rotavirus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D014613:Vaccines, Attenuated / Q000008:administration & dosage
chemical_list: C492457:RIX4414 vaccine; C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated